Gastl G, Denz H, Abbrederis C, Huber H, Troppmair J, Wiegele J, Niederwieser D, Flener R, Huber C
Onkologie. 1985 Jun;8(3):143-4. doi: 10.1159/000215641.
Five cases with advanced hairy cell leukemia refractory to treatment with splenectomy and chemotherapy as well as one patient presenting with a stage-A response to splenectomy were treated with rhu-IFN-alpha 2-arg. 5 X 10(6) were administered intramuscularly every day. Both patients, with advanced disease resistant to conventional therapy and treated for six or more months with rhu-IFN-alpha 2-arg, achieved complete clinical remissions. Three further cases treated for less than half a year and also with advanced disease achieved partial remission states with marked reduction of circulating hairy cells and with recovery of normal hemopoiesis. Minimal residual disease in the remaining patient during a three-month period of treatment did not respond. Side effects of rhu-IFN-alpha 2 low dose therapy were minimal in 5 cases and comprised a severe leukopenia reversible after dose reduction in one patient.
5例晚期毛细胞白血病患者，对脾切除和化疗均耐药，还有1例患者脾切除后呈A期反应，均接受重组人干扰素α 2a治疗。每天肌肉注射5×10⁶单位。这2例对传统治疗耐药的晚期疾病患者，接受重组人干扰素α 2a治疗6个月或更长时间后，均实现了完全临床缓解。另外3例病程晚期且治疗时间不足半年的患者，实现了部分缓解，循环中的毛细胞显著减少，正常造血功能恢复。剩余1例患者在3个月的治疗期间，微小残留病无反应。5例患者中，低剂量重组人干扰素α 2治疗的副作用极小，1例患者出现严重白细胞减少，减少剂量后可逆转。
